Skip to content
Politically.com Search all
Menu

2026 · 3rd Quarter (July 1 - Sep 30)

SUN PHARMACEUTICAL INDUSTRIES, INC.

Filed by SUN PHARMACEUTICAL INDUSTRIES, INC..

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-11-02 06:26:10 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 20, 2026
Income
Not reported
Expenses
$140,000.00
Filing UUID
41605f76-9618-446c-85e8-a4f892112c45
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

H.R. 5526 - Biosimilar Red Tape Elimination Act; all provisions. S. 1414 - Expedited Access to Biosimilars Act; all provisions. S. 2658 - Medication Affordability and Patent Integrity Act; all provisions.

Literal federal measure citations: H.R. 5526, S. 1414, S. 2658

TRD · Trade (domestic/foreign)

Issues related to Section 232 pharmaceutical tariffs.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.